US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,478.45

-13.6379-0.91%

Number of Gainers:3

Number of Losers:4

Number of Flat:- -

PE:- -

High:1,485.06

Open:1,483.83

Low:1,470.83

Close:1,492.17

Loading ...

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Jim Cramer on Novo Nordisk A/S (NVO): ‘Where Are They Going To Be In The Tariffs’

Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial

MT Newswires Live

BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59

Pfizer: European Commission to Review Chmp Recommendation and Is Expected to Make Final Decision in Coming Months

THOMSON REUTERS

Pfizer’s Abrysvo Gets Positive Chmp Opinion for Adults Aged 18 to 59

THOMSON REUTERS

Novo Nordisk added to European Conviction List at Goldman Sachs

Where Will Eli Lilly Be in 5 Years?

Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?

Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire

Positive Results From Tezspire® (Tezepelumab-Ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect in Chronic Rhinosinusitis With Nasal Polyps

THOMSON REUTERS

POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

Pfizer (NYSE:PFE) Has A Pretty Healthy Balance Sheet

Simply Wall St.

Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note

Amgen Inc. (AMGN) Invests $200M in AI-Focused Tech Center in India, Plans to Hire 2,000 by 2025

AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4599/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1478.5353,"timestamp":1741278723685,"preClose":1492.1732,"halted":0,"volume":16645166,"delay":0,"changeRate":-0.00914,"change":-13.637939,"pbRate":11.780703,"amount":1664556604.158231,"amplitude":0.00954,"prevYearClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"turnoverRate":0.001577,"marketCap":1590120967552,"floatMarketCap":1476952826368,"peRate":41.703544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1485.0612,"amplitude":0.00954,"preClose":1492.1732,"low":1470.8256,"pbRate":"11.780703","latestPrice":1478.4548,"volume":16645643,"delay":0,"open":1483.8325,"prevYearClose":1305.0607,"prevWeekClose":1482.1702,"prevMonthClose":1482.1702,"prevQuarterClose":1305.0607,"fiveDayClose":1460.4895,"twentyDayClose":1394.0055,"sixtyDayClose":1438.0239,"secType":"PLATE","market":"US","turnoverRate":0.001577,"peRate":41.703544,"marketCap":1590120967552,"floatMarketCap":1476952826368,"timestamp":1741278724917,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":3,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516653947","title":"Are You a Value Investor? This 1 Stock Could Be the Perfect Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=2516653947","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516653947?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:40","pubTimestamp":1741012811,"startTime":"0","endTime":"0","summary":"It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why Investors Should Pay Attention to This Value Stock. Finding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks.A company's earnings performance is important for value investors as well. For fiscal 2025, eight analysts revised their earnings estimate higher in the last 60 days","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/value-investor-1-stock-could-144011278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1983299246.USD","BK4585","IE00B4R5TH58.HKD","BK4533","IE0002141913.USD","SG9999001440.SGD","IE00BJJMRZ35.SGD","BK4599","LU0058720904.USD","IE0009355771.USD","LU1057294990.SGD","BK4534","LU0109394709.USD","AMGN","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1571399168.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0320765992.SGD","BK4581","BK4139","LU1023059063.AUD","LU0122379950.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU1061106388.HKD","BK4566","BK4588","LU0289739699.SGD","LU2112291526.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2516634459","title":"Jim Cramer on Novo Nordisk A/S (NVO): ‘Where Are They Going To Be In The Tariffs’","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634459","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634459?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:37","pubTimestamp":1741012669,"startTime":"0","endTime":"0","summary":"We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate.In this article, we are going to take a look at where Novo Nordisk A/S  stands against the other stocks.In a recent appearance on CNBC's Squawk on the Street, Jim Cramer commented on a late-hours market selloff. Cramer shared that he was \"tired of it [the selloff]. I'm tired because it just seems totally artificial. I mean someone comes in and blitzes the market in the last twenty minutes.\" He believes \"There's no reason to do that other than you wanna take it down. I don't know why, I've seen this periodically in my career. These are, what I regard as being, deliberate. Not manipulation, because that's too strong.\". As for the spending cuts, he commented on a recent media article that \"says is, alright, they did the little guys. Now, here comes the big guys. And we all would say that defense has too much spending. And by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jim-cramer-novo-nordisk-nvo-143749166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVO","LU1093756325.SGD","BK4585","BK4599","LU1093756168.USD","BK4588","LU0154236417.USD","BK4532"],"gpt_icon":1},{"id":"2516180687","title":"Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516180687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516180687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:59","pubTimestamp":1741003188,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Saturday the full results from the Phase III trial showed Tezspire or tezepelumab, an asthma treatment jointly developed with Amgen , led to significant reductions in nasal polyp severity, surgery requirements, and systemic corticosteroid use for patients with chronic rhinosinusitis with nasal polyps, compared with placebo.At week 52, Tezspire improved the co-primary endpoints, reducing Nasal Polyp Score by -2.065 and nasal congestion by -1.028 compared with placebo, with benefits observed as early as weeks four and two respectively.These findings were published in the New England Journal of Medicine and presented at the American Academy of Allergy Asthma & Immunology and World Allergy Organization Joint Congress in San Diego, California on Saturday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","BK4534","BK4139","LU2242646821.SGD","LU2112291526.USD","LU2417539215.USD","LU0058720904.USD","BK4581","IE00BJJMRZ35.SGD","BK4134","LU1023059063.AUD","LU1057294990.SGD","BK4568","LU2236285917.USD","LU2242652126.USD","AMGN","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4599","BK4533","LU1983299246.USD","AZN","BK4588","BK4566","III","LU1061106388.HKD","LU2462157665.USD","LU2456880835.USD","BK4007","IE00B2B36J28.USD","LU1829250122.USD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","IE0002141913.USD","SG9999001440.SGD","IE0009355771.USD","LU0122379950.USD","LU0868494617.USD","LU1571399168.USD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2516683029","title":"BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683029","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683029?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:43","pubTimestamp":1740994996,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59March 3  - Pfizer Inc PFE.N:PFIZER’S ABRYSVO GETS POSITIVE CHMP OPINION FOR ADULTS AGED 18 TO 59PFIZER: EUROPEAN COMMISSION TO REVIEW CHMP RECOMMENDATION AND IS EXPECTED TO MAKE FINAL DECISION IN COMING MONTHSFurther company coverage: PFE.N ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","IE0002270589.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00BBT3K403.USD","BK4534","LU0122379950.USD","LU1894683264.USD","BK4592","IE00BLSP4239.USD","BK4588","LU1894683348.USD","LU0289739699.SGD","LU0868494617.USD","LU1066053197.SGD","SG9999013999.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4007","IE00B19Z3581.USD","LU0306806265.USD","LU1066051498.USD","LU0321505868.SGD","BK4585","LU1883839398.USD","LU0170899867.USD","LU0306807586.USD","LU0225284248.USD","SG9999002232.USD","BK4581","IE00B19Z3B42.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","BK4568","LU0058720904.USD","SGXZ57979304.SGD","SG9999001176.USD","LU0225771236.USD","LU0456855351.SGD","PFE","BK4533","BK4599","LU0985481810.HKD","LU0234572021.USD"],"gpt_icon":0},{"id":"2516868394","title":"Pfizer: European Commission to Review Chmp Recommendation and Is Expected to Make Final Decision in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2516868394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516868394?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:32","pubTimestamp":1740994338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999002224.SGD","BK4581","LU0456855351.SGD","LU0868494617.USD","LU0234572021.USD","LU1057294990.SGD","LU0321505439.SGD","SG9999011175.SGD","BK4585","LU0985481810.HKD","SG9999001176.USD","BK4534","LU0225284248.USD","LU1883839398.USD","BK4007","SGXZ57979304.SGD","BK4588","BK4592","LU1894683264.USD","IE000M9KFDE8.USD","LU0225771236.USD","IE00BLSP4239.USD","BK4568","LU1066051498.USD","IE00BBT3K403.USD","PFE","SG9999013999.USD","LU0321505868.SGD","LU1066053197.SGD","LU1894683348.USD","IE00B19Z3581.USD","LU1023059063.AUD","LU0289739699.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","SG9999003800.SGD","BK4599","BK4533","IE0002270589.USD","LU0058720904.USD","BK4550","IE00B19Z3B42.SGD","SG9999002232.USD","LU0122379950.USD","LU0170899867.USD","LU0306806265.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"2516683916","title":"Pfizer’s Abrysvo Gets Positive Chmp Opinion for Adults Aged 18 to 59","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683916?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:32","pubTimestamp":1740994338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BBT3K403.USD","SG9999011175.SGD","BK4534","LU0225771236.USD","LU0289739699.SGD","PFE","BK4592","LU0306807586.USD","LU0306806265.USD","BK4599","LU0456855351.SGD","LU1066053197.SGD","BK4007","LU0234572021.USD","SG9999001176.USD","BK4588","SG9999002232.USD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU0321505439.SGD","LU1057294990.SGD","IE00B19Z3B42.SGD","BK4550","BK4585","BK4568","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0321505868.SGD","SG9999002224.SGD","LU0058720904.USD","IE00BLSP4452.SGD","LU0868494617.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","LU0985481810.HKD","SG9999013999.USD","LU0225284248.USD","LU1894683264.USD","BK4533","BK4581","IE000M9KFDE8.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2516856356","title":"Novo Nordisk added to European Conviction List at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2516856356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516856356?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:25","pubTimestamp":1740993912,"startTime":"0","endTime":"0","summary":"Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent share p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-added-to-european-conviction-list-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-added-to-european-conviction-list-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1668664300.SGD","IE0004086264.USD","LU2471134796.USD","BK4532","LU2237438978.USD","LU2237443622.USD","IE00B19Z3581.USD","LU2237443895.HKD","IE0002270589.USD","BK4007","LU2237443549.SGD","BK4585","BK4516","BK4599","LU1093756325.SGD","LU2237443978.SGD","LU1868837300.USD","IE00BZ1G4Q59.USD","LU2237443382.USD","LU0061475181.USD","BK4550","IE00B19Z3B42.SGD","LU1868837136.USD","LU2750360997.AUD","IE0034235188.USD","BK4533","LU0154236417.USD","NVO","BK4127","LU2750360641.GBP","LU1093756168.USD","LU0096364046.USD","LU2471134952.CNY","LU1868836914.USD","LU1868836591.USD","IE00BFXG1179.USD","LU2471134879.HKD","IE00BSNM7G36.USD","LU1791807156.HKD","LU2471134523.USD","BK4504","IE0004091025.USD","LU0106831901.USD","LU1868836757.USD","LU2237443465.HKD","BK4552","IE00BKVL7J92.USD","BK4588"],"gpt_icon":0},{"id":"2516542866","title":"Where Will Eli Lilly Be in 5 Years?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516542866","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516542866?lang=en_us&edition=fundamental","pubTime":"2025-03-03 03:39","pubTimestamp":1740944340,"startTime":"0","endTime":"0","summary":"Eli Lilly is set to keep growing its revenue at a strong pace in the next five years.It's hard to argue with the kinds of results Eli Lilly  has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares leaving the broader market in the dust.Some might argue that it's too late for investors to get in on Eli Lilly, while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option. Which side is right?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/02/where-will-eli-lilly-be-in-5-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0061475181.USD","LU1280957306.USD","GB00BDT5M118.USD","BK4007","LU0708995401.HKD","SG9999015952.SGD","SG9999017495.SGD","LU1267930730.SGD","LU2237443465.HKD","LLY","LU0097036916.USD","BK4599","LU1804176565.USD","LU0289739699.SGD","LU1551013342.USD","LU1291159041.SGD","LU1868837300.USD","LU0640476718.USD","SG9999018865.SGD","LU1127390331.HKD","LU0820561818.USD","LU1093756168.USD","LU1868836591.USD","SGXZ31699556.SGD","LU1989771016.USD","SG9999001176.SGD","SG9999018857.SGD","LU2491050071.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU0417517546.SGD","IE00B1BXHZ80.USD","BK4516","SG9999015986.USD","LU0122379950.USD","LU0114720955.EUR","LU1548497426.USD","LU1035775433.USD","SG9999013999.USD","LU2461242641.AUD","IE00B2B36J28.USD","LU2602419157.SGD","LU2361044949.HKD","LU2360106947.USD","LU2106854487.HKD","LU2324357040.USD","LU0006306889.USD","LU0943347566.SGD","LU1720051017.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2516404545","title":"Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stocks to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516404545","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516404545?lang=en_us&edition=fundamental","pubTime":"2025-03-03 01:16","pubTimestamp":1740935800,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now.In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.  stands against the other small cap pharma stocks.Impact of US Tariffs and Obesity Drug Performance on the Pharmaceutical Industry. Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical industry. According to her, the industry might not perform poorly at least in the first half of this year. The effectiveness of obesity medications is still up for debate, though, as leading companies in the field have shown inconsistent results.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/supernus-pharmaceuticals-inc-supn-best-171640328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0471298777.SGD","LU2063271972.USD","MNQmain","LU0006306889.USD","LU0708995401.HKD","SG9999014898.SGD","SGXZ31699556.SGD","SUPN","LU0320765059.SGD","LU0385154629.USD","LU0820561909.HKD","LU0256863902.USD","IE00BFTCPJ56.SGD","BK4516","LU1064131342.USD","TQQQ","IE00BJT1NW94.SGD","LU2237443978.SGD","LU0061475181.USD","LU2264538146.SGD","LU0058720904.USD","LU0882574055.USD","SQQQ","LU0106261372.USD","LU2237443549.SGD",".IXIC","BK4599","LU2237443465.HKD","IE00BJJMRZ35.SGD","NQmain","ABVC","LU1267930730.SGD","LLY","LU1868836757.USD","LU0114720955.EUR","QLD","LU1280957306.USD","LU0354030511.USD","LU1974910355.USD","NVIW.SI","USJW.SI","TSYW.SI","USAW.SI","LU1712237335.SGD","IE00B1BXHZ80.USD","LU0823416689.USD","PSQ","LU2491049909.HKD","QID"],"gpt_icon":1},{"id":"2516517473","title":"Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire","url":"https://stock-news.laohu8.com/highlight/detail?id=2516517473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516517473?lang=en_us&edition=fundamental","pubTime":"2025-03-02 22:10","pubTimestamp":1740924616,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-results-from-phase-3-waypoint-trial-on-tezspire?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-results-from-phase-3-waypoint-trial-on-tezspire?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4139","LU0320765992.SGD","BK4533","BK4566","LU0058720904.USD","LU2462157665.USD","LU2112291526.USD","LU1829250122.USD","AMGN","BK4599","LU1023059063.AUD","BK4585","LU2236285917.USD","BK4568","SG9999001440.SGD","LU1571399168.USD","IE0002141913.USD","LU0122379950.USD","LU0289739699.SGD","IE00B2B36J28.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","BK4534","IE00B4R5TH58.HKD","LU2242646821.SGD","LU2417539215.USD","LU0868494617.USD","AZN","LU2242652126.USD","LU2456880835.USD","BK4007","LU1061106388.HKD","BK4581","LU1983299246.USD","IE00BJT1NW94.SGD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2516564683","title":"Positive Results From Tezspire® (Tezepelumab-Ekko) Phase 3 Waypoint Trial Highlight Rapid, Sustained Effect in Chronic Rhinosinusitis With Nasal Polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2516564683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516564683?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250301:nTUABPTQMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","BK4534","BK4139","LU2242646821.SGD","LU2112291526.USD","LU0058720904.USD","BK4581","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1057294990.SGD","LU2242652126.USD","AMGN","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4599","BK4533","LU1983299246.USD","BK4588","BK4566","LU1061106388.HKD","IE00B2B36J28.USD","LU0320765992.SGD","LU0289739699.SGD","LU0109394709.USD","IE0002141913.USD","SG9999001440.SGD","IE0009355771.USD","LU0122379950.USD","LU0868494617.USD","LU1571399168.USD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2516564150","title":"POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2516564150","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516564150?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery. Data Published in NEJM and Presented at AAAAI/WAO 2025. THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen  and AstraZeneca today announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly reduced nasal polyp severity, the need for surgery and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 The data were published today in the New England Journal of Medicineand were highlighted as a late-breaking oral presentation during the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego.1,2. \"Chronic rhinosinusitis with nasal polyps is a recurrent condition often requiring repeat courses of systemic corticosteroids, even for patients on currently available biologics, and can require repeat surgeries,\" said Jay Bradner, M.D., executi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-tezepelumab-ekko-223000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0532188223.SGD","IE00BJT1NW94.SGD","SG9999014484.SGD","BK4534","TSLP","SG9999002414.USD","LU2242646821.SGD","LU0516422952.EUR","LU0048573645.USD","LU0737861269.HKD","BK4581","IE00BJJMRZ35.SGD","FL","BK4503","LU0261945553.USD","LU1023059063.AUD","SG9999002620.SGD","LU2242652126.USD","AMGN","LU0889565916.HKD","LU2045819591.USD","SG9999004360.SGD","TSS","SGXZ58947870.SGD","SG9999013478.USD","IE0034224299.USD","LU1242518857.USD","BK4599","LU0572940350.SGD","SG9999006266.SGD","LU1983299246.USD","LU0251143029.SGD","SG9999013486.USD","BK4588","LU0210637038.USD","LU1061106388.HKD","LU1242518931.SGD","SG9999013460.SGD","LU0516423091.SGD","LU0320765992.SGD","LU0289739699.SGD","IE0002141913.USD","LU0572939691.SGD","SG9999001440.SGD","BK4535","LU0264606111.USD","SG9999002406.SGD","BK4585","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2516552661","title":"Pfizer (NYSE:PFE) Has A Pretty Healthy Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552661","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516552661?lang=en_us&edition=fundamental","pubTime":"2025-03-01 22:00","pubTimestamp":1740837617,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We can see that Pfizer Inc.  does use debt in its business. But should shareholders be worried about its use of debt?Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more usual  situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-nyse-pfe-pretty-healthy-140017905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","BK4533","LU0321505868.SGD","LU1894683348.USD","LU0122379950.USD","SG9999003800.SGD","LU1894683264.USD","LU0306807586.USD","LU1057294990.SGD","LU0225284248.USD","BK4007","BK4534","BK4599","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0170899867.USD","IE0002270589.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","SG9999011175.SGD","SG9999002224.SGD","LU0225771236.USD","LU0985481810.HKD","BK4581","PFE","LU0868494617.USD","NYSE","EBIT","LU1066051498.USD","LU0306806265.USD","BK4592","LU0289739699.SGD","BK4550","BK4568","SGXZ57979304.SGD","IE000M9KFDE8.USD","BK4585","SG9999001176.SGD","LU0456855351.SGD","LU0058720904.USD","SG9999002232.USD","IE00BLSP4239.USD","LU1883839398.USD","LU1023059063.AUD","LU0234572021.USD","SG9999013999.USD","BK4588"],"gpt_icon":1},{"id":"2516589974","title":"Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589974","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516589974?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:45","pubTimestamp":1740782719,"startTime":"0","endTime":"0","summary":"In the latest trading session, Viking Therapeutics, Inc.  closed at $28.87, marking a +0.7% move from the previous day. This move lagged the S&P 500's daily gain of 1.59%. Meanwhile, the Dow experienced a rise of 1.39%, and the technology-dominated Nasdaq saw an increase of 1.63%.Coming into today, shares of the company had lost 14.9% in the past month. In that same time, the Medical sector lost 0.63%, while the S&P 500 lost 2.42%.Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$0.34 per share. This would mark a year-over-year decline of 30.77%.Investors might also notice recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viking-therapeutics-inc-vktx-ascends-224519390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4599","BK4588","VKTX","BK4585","BK4139"],"gpt_icon":1},{"id":"2516466300","title":"Amgen Inc. (AMGN) Invests $200M in AI-Focused Tech Center in India, Plans to Hire 2,000 by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516466300","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516466300?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:37","pubTimestamp":1740782264,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street.In this article, we are going to take a look at where Amgen Inc.  stands against the other AI stocks.In a recent discussion at CNBC's 'Squawk on the Street', NYU professor and AI expert, Gary Marcus shared his perspective on the limitations of current AI models, the hurdles in enterprise adoption, and the financial sustainability of major AI companies. His insights raise important questions about the future of AI and whether it can truly deliver on its ambitious promises.AI’s Future Faces Hurdles in Reliability, Costs, and Enterprise Use. At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-inc-amgn-invests-200m-223744169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","LU0320765992.SGD","PSQ","TSYW.SI","LU2112291526.USD","AMGN","BK4534","TQQQ","BK4533","LU1571399168.USD","LU0109394709.USD","LU1057294990.SGD","BK4588","LU2242652126.USD","LU1023059063.AUD","NVIW.SI","LU0122379950.USD","QID","MNQmain","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4566","IE00BJJMRZ35.SGD",".IXIC","NQmain","SG9999001440.SGD","BK4139","LU0289739699.SGD","BK4599","LU0868494617.USD","LU1983299246.USD","IE0009355771.USD","BK4581","IE0002141913.USD","IE00BFTCPJ56.SGD","SQQQ","IE00B2B36J28.USD","LU2242646821.SGD","LU0058720904.USD","LU0889565916.HKD","QLD","LU1061106388.HKD","BK4585","USJW.SI"],"gpt_icon":1},{"id":"2516830105","title":"AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE","url":"https://stock-news.laohu8.com/highlight/detail?id=2516830105","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516830105?lang=en_us&edition=fundamental","pubTime":"2025-03-01 05:01","pubTimestamp":1740776460,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ --Amgen  will present at the 45th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner, executive vice president of Research and Development at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.For more information, visit Amgen.comand follow us on X, LinkedIn, Instagram,YouTubeand Threads.CONTA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-present-45th-annual-td-210100755.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-present-45th-annual-td-210100755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1057294990.SGD","IE00BFTCPJ56.SGD","COWN","BK4139","LU1571399168.USD","LU0058720904.USD","IE0002141913.USD","LU1061106388.HKD","LU2242646821.SGD","AMGN","BK4534","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU0289739699.SGD","CARE","LU0889565916.HKD","LU1023059063.AUD","IE00B2B36J28.USD","BK4211","BK4533","IE0009355771.USD","LU2242652126.USD","BK4207","BK4581","TD","LU2112291526.USD","LU0868494617.USD","LU0320765992.SGD","LU0122379950.USD","BK4599","LU0109394709.USD","BK4585","IE00B4R5TH58.HKD","BK4566","BK4127","LU1983299246.USD","BK4588","IE00BJT1NW94.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":15,"pageCount":5,"totalSize":225}]}}